An investigation for investors in NASDAQ:VTAE shares was announced over the takeover of Vitae Pharmaceuticals Inc by Allergan plc.
Investors who purchased shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) and currently hold any of those NASDAQ:VTAE shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Vitae Pharmaceuticals directors breached their fiduciary duties owed to NASDAQ:VTAE investors in connection with the proposed acquisition.
On September 14, 2016, Allergan plc (NYSE:AGN) and Vitae Pharmaceuticals Inc (NASDAQ:VTAE) announced that they have entered into an agreement under which Allergan will acquire Vitae Pharmaceuticals Inc (NASDAQ:VTAE) for $21.00 per share, in cash, for a total transaction value of approximately $639 million.
However, the investigation concerns whether the offer is unfair to NASDAQ:VTAE stockholders. More specifically, the investigation concerns whether the Vitae Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders’ best interests in connection with the proposed sale.
On September 26, 2016, NASDAQ: VTAE shares closed at $20.90 per share.
Those who are current investors in NASDAQ:VTAE shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego